Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 5, 2020
Previous Article Next Article

Recent progress on phenotype-based discovery of dengue inhibitors

Author affiliations

Abstract

Dengue fever is the world's most prevalent mosquito-borne viral disease caused by the four serotypes of dengue virus, which are widely spread throughout tropical and sub-tropical countries. There has been an urgent need to identify an effective and safe dengue inhibitor as a therapeutic and a prophylactic agent for dengue fever. Most clinically approved antiviral drugs for the treatment of human immunodeficiency syndrome-1 (HIV-1) and hepatitis C virus (HCV) target virally encoded enzymes such as protease or polymerase. Inhibitors of these enzymes were typically identified by target-based screening followed by optimization via structure-based design. However, due to the lack of success to date of research efforts to identify dengue protease and polymerase inhibitors, alternative strategies for anti-dengue drug discovery need to be considered. As a complementary approach to the target-based drug discovery, phenotypic screening is a strategy often used in identification of new chemical starting points with novel mechanisms of action in the area of infectious diseases such as antibiotics, antivirals, and anti-parasitic agents. This article is an overview of recent reports on dengue phenotypic screens and discusses phenotype-based hit-to-lead chemistry optimization. The challenges encountered and the outlook on dengue phenotype-based lead discovery are discussed at the end of this article.

Graphical abstract: Recent progress on phenotype-based discovery of dengue inhibitors

Back to tab navigation

Article information


Submitted
15 Feb 2020
Accepted
24 Mar 2020
First published
20 Apr 2020

RSC Med. Chem., 2020,11, 541-551
Article type
Review Article

Recent progress on phenotype-based discovery of dengue inhibitors

F. Yokokawa, RSC Med. Chem., 2020, 11, 541
DOI: 10.1039/D0MD00052C

Social activity

Search articles by author

Spotlight

Advertisements